Published in Med Hypotheses on March 26, 2007
Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol (2012) 1.21
Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol Vis (2011) 0.88
Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol (2015) 0.82
Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol (2013) 0.80
A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. Int Ophthalmol (2015) 0.79
Correlation between NGF/TrkA and microvascular density in human pterygium. Int J Exp Pathol (2009) 0.78
Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. J Ocul Pharmacol Ther (2014) 0.78
Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. Indian J Ophthalmol (2014) 0.77
Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. Clin Ophthalmol (2013) 0.77
Prophylactic effect of topical silica nanoparticles as a novel antineovascularization agent for inhibiting corneal neovascularization following chemical burn. Adv Biomed Res (2015) 0.76
Efficacy of curcumin in inducing apoptosis and inhibiting the expression of VEGF in human pterygium fibroblasts. Int J Mol Med (2017) 0.75
Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence. J Ophthalmol (2017) 0.75
Preoperative subconjunctival combined injection of bevacizumab and mitomycin C before the surgical excision of primary pterygium: clinical and histological results. Clin Ophthalmol (2017) 0.75
Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol (2007) 1.64
Comparison of corneal thickness measurements using Galilei, HR Pentacam, and ultrasound. Cornea (2010) 1.04
A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses (2006) 1.00
Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina (2009) 0.95
Bilateral spontaneous rupture of posterior capsule in posterior polar cataract. Clin Experiment Ophthalmol (2008) 0.94
Comparative study of Gram stain, potassium hydroxide smear, culture and nested PCR in the diagnosis of fungal keratitis. Ophthalmic Res (2010) 0.93
Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina (2012) 0.93
Cone location and correction of keratoconus with rigid gas-permeable contact lenses. Cont Lens Anterior Eye (2011) 0.89
Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea (2012) 0.84
Effect of anterior chamber air bubble on prevention of experimental Staphylococcus epidermidis endophthalmitis. Graefes Arch Clin Exp Ophthalmol (2009) 0.81
Detection of Aspergillus keratitis in ocular infections by culture and molecular method. Int Ophthalmol (2011) 0.79
Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK). Med Hypotheses (2007) 0.77
Debate on the various anti-vascular endothelial growth factor drugs. Indian J Ophthalmol (2008) 0.75